- Home
- OCGN
OCGN
Ocugen Inc.
as 11-22-2024 4:00pm EST
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | MALVERN |
| Market Cap: | 252.4M | IPO Year: | N/A |
| Target Price: | $5.67 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.36 - $2.10 | Next Earning Date: | 11-08-2024 |
| Revenue: | $4,700,000 | Revenue Growth: | -33.94% |
| Revenue Growth (this year): | -53.48% | Revenue Growth (next year): | N/A |
Latest Ocugen Inc. News
OCGN Breaking Stock News: Dive into OCGN Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Ocugen's Eye Disease Treatment Receives Orphan Drug Designation in Europe for Retinopathies
GlobeNewswire
4 days ago
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
GlobeNewswire
5 days ago
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Zacks
9 days ago
Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates
Associated Press Finance
9 days ago
Ocugen: Q3 Earnings Snapshot
Thomson Reuters StreetEvents
15 days ago
Q3 2024 Ocugen Inc Earnings Call
GuruFocus.com
15 days ago
Ocugen Inc (OCGN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
Motley Fool
15 days ago
Ocugen (OCGN) Q3 2024 Earnings Call Transcript
Compare OCGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OCGN Ocugen Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.